Astellas Pharma (FRA:YPHA) Cyclically Adjusted Book per Share: €4.45 (As of Mar. 2026)


FRA:YPHA Astellas Pharma Inc FRA:YPHA
82 GF Score
Price €11.00
GF Value €11.53
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Cyclically Adjusted Book per Share?

Astellas Pharma FRA:YPHA -2.65% 82 Cyclically Adjusted Book per Share is €4.45 as of Mar. 2026. GuruFocus rates FRA:YPHA with a GF Score™ of 82/100 and a GF Value™ of €11.53 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Astellas Pharma's adjusted book value per share for the three months ended in Mar. 2026 was €5.565. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €4.45 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Astellas Pharma's average Cyclically Adjusted Book Growth Rate was 4.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 5.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Astellas Pharma was 7.40% per year. The lowest was 4.00% per year. And the median was 5.90% per year.

As of today (2026-07-02), Astellas Pharma's current stock price is €11.00. Astellas Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €4.45. Astellas Pharma's Cyclically Adjusted PB Ratio of today is 2.47.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Astellas Pharma was 3.62. The lowest was 1.58. And the median was 2.79.


Astellas Pharma  (FRA:YPHA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Astellas Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=11.00/4.45
=2.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Astellas Pharma was 3.62. The lowest was 1.58. And the median was 2.79.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Astellas Pharma Cyclically Adjusted Book per Share Related Terms


Astellas Pharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Cyclically Adjusted Book per Share Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.71 4.75 4.49 4.82 4.45

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.82 4.60 4.51 4.40 4.45

FRA:YPHA vs LLY, JNJ, ABBV: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted PB Ratio falls into.


FRA:YPHA
82GF Score
Astellas Pharma Inc FRA:YPHA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=5.565/112.7000*112.7000
=5.565

Current CPI (Mar. 2026) = 112.7000.

Astellas Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 4.889 98.100 5.617
201609 5.223 98.000 6.006
201612 5.219 98.400 5.977
201703 5.100 98.100 5.859
201706 5.348 98.500 6.119
201709 5.039 98.800 5.748
201712 5.070 99.400 5.748
201803 4.905 99.200 5.573
201806 5.059 99.200 5.747
201809 5.102 99.900 5.756
201812 5.267 99.700 5.954
201903 5.313 99.700 6.006
201906 5.423 99.800 6.124
201909 5.799 100.100 6.529
201912 5.820 100.500 6.527
202003 5.834 100.300 6.555
202006 5.807 99.900 6.551
202009 5.756 99.900 6.494
202012 5.835 99.300 6.622
202103 5.781 99.900 6.522
202106 5.625 99.500 6.371
202109 5.903 100.100 6.646
202112 6.152 100.100 6.926
202203 6.120 101.100 6.822
202206 5.948 101.800 6.585
202209 6.364 103.100 6.957
202212 6.014 104.100 6.511
202303 5.864 104.400 6.330
202306 5.736 105.200 6.145
202309 5.782 106.200 6.136
202312 5.340 106.800 5.635
202403 5.466 107.200 5.746
202406 5.512 108.200 5.741
202409 5.387 108.900 5.575
202412 5.181 110.700 5.275
202503 5.245 111.100 5.321
202506 4.964 111.700 5.008
202509 5.187 112.000 5.219
202512 5.391 113.000 5.377
202603 5.565 112.700 5.565

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €4.45 mean?
Astellas Pharma (FRA:YPHA) has a Cyclically Adjusted Book per Share of €4.45 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Cyclically Adjusted Book per Share too high?
Astellas Pharma's current Cyclically Adjusted Book per Share is €4.45. Overall, Astellas Pharma has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Cyclically Adjusted Book per Share compare to LLY and JNJ?
Astellas Pharma's Cyclically Adjusted Book per Share of €4.45 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Cyclically Adjusted Book per Share is €4.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (FRA:YPHA) is currently considered Fairly Valued. The stock's GF Value™ is €11.53, compared to a current price of €11.00 — trading 4.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is €4.45. Astellas Pharma's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Astellas Pharma (FRA:YPHA), the current Cyclically Adjusted Book per Share is €4.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (FRA:YPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of €11.00 is trading 4.6% below its estimated GF Value™ of €11.53. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for FRA:YPHA:

  • Cyclically Adjusted Book per Share: €4.45
  • GF Value™: €11.53 vs. price of €11.00 (4.6% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the FRA:YPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
82GF Score

Get the complete analysis for FRA:YPHA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.00
Price
€11.53
GF Value